Functions and mechanisms of lactylation in carcinogenesis and immunosuppression

Front Immunol. 2023 Aug 14:14:1253064. doi: 10.3389/fimmu.2023.1253064. eCollection 2023.

Abstract

As critical executors regulating many cellular operations, proteins determine whether living activities can be performed in an orderly and efficient manner. Precursor proteins are inert and must be modified posttranslationally to enable a wide range of protein types and functions. Protein posttranslational modifications (PTMs) are well recognized as being directly associated with carcinogenesis and immune modulation and have emerged as important targets for cancer detection and treatment. Lactylation (Kla), a novel PTM associated with cellular metabolism found in a wide range of cells, interacts with both histone and nonhistone proteins. Unlike other epigenetic changes, Kla has been linked to poor tumor prognosis in all current studies. Histone Kla can affect gene expression in tumors and immunological cells, thereby promoting malignancy and immunosuppression. Nonhistone proteins can also regulate tumor progression and treatment resistance through Kla. In this review, we aimed to summarize the role of Kla in the onset and progression of cancers, metabolic reprogramming, immunosuppression, and intestinal flora regulation to identify new molecular targets for cancer therapy and provide a new direction for combined targeted therapy and immunotherapy.

Keywords: Warburg effect; immunosuppression; lactylation (Kla); metabolic reprogramming; tumor microenvironment (TME).

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Carcinogenesis
  • Epigenesis, Genetic
  • Histones*
  • Humans
  • Immunosuppression Therapy*
  • Immunotherapy

Substances

  • Histones

Grants and funding

This work was supported by the Jilin Provincial Science and Technology Foundation (grant number 20210402002GH and 20230508064RC), the Achievement Transformation Guiding Foundations of First Hospital of Jilin University (grant number CGZHYD202012-029).